BioSpace News Archive

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at the Festival of Biologics occurring March 2-4, 2020 in San Diego, CA.

The MemorialCare Heart & Vascular Institute at Long Beach Medical Center is the only hospital in Southern California — and one of only four sites in all of California — participating in the Dual Epicardial and Endocardial Procedure clinical trial.

Innocoll Holdings Limited, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, announced today that it has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for XARACOLL® (bupivacaine HCl collagen-matrix implants), an investigational drug-device for the management of postsurgical pain after open inguinal hernia surgery.

Ubiquitin Conjugating Enzyme serves as key target to BERG’s oncology therapeutics discovery efforts

Simparica Trio marks the first all-in-one protection in the U.S. against heartworm disease, ticks* and fleas, roundworms and hookworms** in a single monthly chewable

Levity Products Incorporated is pleased to announce the release of a set of newly patented and clinically proven external catheter stabilizers, a new medical device known as The LECS that is expected to revolutionize the catheter stabilization market

GenomSys has moved two of its teams to the BioPôle in Lausanne, to support the company’s growth and improve its accessibility to the Life Sciences community.

Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), will announce its results for the full year ended 31 December 2019 on Monday 2 March 2020.

Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy, announces that the US Food and Drug Administration (FDA) has approved BARHEMSYS® (amisulpride injection) for the prevention and treatment of PONV in adult patients.

INRS scientists take one step closer towards a better understanding of Batten disease